The Rheumatoid Arthritis Treatment Market is bound to reach US$ 40.5 Bn at a CAGR of 6% between 2021-2031. The modern-day situation says that the healthcare sector is witnessing an optimization and reposition of the business models to obtain enhanced patient outcomes. With real-time analytics known to improve patient care and the fact that consumers are shifting towards the preventive model of care, the healthcare vertical is likely to witness greater strides in the forecast period.
Rising occurrence of rheumatoid arthritis because of shift toward unhealthy lifestyle as well asincreasing research & development activities for better and permanent therapy alternatives for rheumatoid arthritis treatment in order to diminish repeat rates are supporting market development. Rheumatoid arthritis is related with the immune system that leads to inflammation in the joints of the body, and later on the disease affects the muscles, fibrous tissues, tendons, and connective tissues. The load of rheumatoid arthritis (RA), currently incurable and an unending autoimmune disease that basically attacks the joints, is prominent. In 2020, approximately 4.9 million individuals across major regions were affected by rheumatoid arthritis. Manufacturers are focusing on partnerships and expansion of product portfolio by launching technologically advanced products and receiving approval from different government bodies.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22555
The global rheumatoid arthritis treatment market is estimated to be valued at US$ 40.5 Bn in 2021, and is expected to exhibit a CAGR of around 6% over the forecast period (2021 – 2031).
Key Take aways from Market Study
- Under therapy, DMARDs hold maximum value share, owing to increasing awareness associated with their utilization.
- By distribution channel, hospital pharmacies hold a notable revenue share of more than 75% in the market.
- The market North America accounted for a share of over 40% in 2020, and is expected to experience significant growth over the next ten years.
- Europe is the next dominating region with a market share of 28% in 2020, due to well-developed healthcare infrastructure largely supported by the government.
“Rise in prevalence of rheumatoid arthritis along with increase in adoption of DMARD therapies, flourishing combination treatment, and supportive government policies are expected to drive market growth,” says a Persistence Market Research analyst.
Get To Touch in our Expert @ https://www.persistencemarketresearch.com/ask-an-expert/22555
Collaborations and Acquisitions – Imperative Strategy for Market Players
Major companies in the rheumatoid arthritis treatment market are actively engaging in acquisitions and expansions in order to enhance their product portfolios and outreach to a large number of customers. Globally, leading companies are acquiring other companies who are facing a large number of product recalls in the market.
- In April 2021, Novartis signed an initial agreement with Roche to reserve capacity and implement technology transfer for the production of active pharmaceutical ingredient (API) for Roche’s Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid arthritis, which is also being tested in various clinical trials investigating the safety and efficacy in COVID-19-associated pneumonia.
- In October 2020, Johnson & Johnson announced the successful acquisition of Momenta Pharmaceuticals, Inc. (“Momenta”), a company that discovered and developed novel therapies for immune-mediated diseases.
COVID-19 Crisis Impact
Due to the unprecedented pandemic scenario, the healthcare sector has been the central point across regions. As import activities were halted, this adversely affected the finances of a majority of healthcare companies. Every industry, including healthcare, is suffering from supply chain disruptions.
The World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international significance on January 30, 2020. Around 210 countries have been affected by COVID-19. Patients with rheumatoid arthritis who contract COVID-19 infection, according to the Lancet Rheumatology 2020, are at a high risk of experiencing serious symptoms and complications.
Some DMARDs commonly used to treat rheumatoid arthritis, such as hydroxychloroquine drugs, are being investigated as potential therapy for COVID-19. Moreover, other generally used therapies such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for manufacturers of rheumatoid arthritis drugs. For instance,
- Tocilizumab, a drug originally used for rheumatoid arthritis, is seeing increased use in treating severe COVID-19 patients.
- A drug developed for rheumatoid arthritis by global pharma company Roche is licensed exclusively to Indian pharma company Cipla.
Access Full Report @ https://www.persistencemarketresearch.com/checkout/22555
What else is in the report?
Persistence Market Research offers a unique perspective and actionable insights on the rheumatoid arthritis treatment market in its latest study, presenting a historical demand assessment of 2016 – 2020 and projections for 2021–2031, based on therapy (symptomatic treatment, intermediate corticosteroid therapies, stem cell therapy/ cell therapy, and disease-modifying anti-rheumatic drugs (DMARDs)) and distribution channel (hospital pharmacies, retail pharmacies, and drug stores), across seven key regions of the world.
Persistence Market Research, as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – firstname.lastname@example.org